Exchange: NYSEMkt·Updated 07:50 PM EDT
News
all
press releases
NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola
The biotech firm said it is progressing towards a Phase II clinical trial of its antiviral drug NV-387 for the Bundibugyo Ebola outbreak in the Democratic Republic of Congo.
Stocktwits
NNVC Stock Up 17% Today: What’s Driving The Rally?
U.S. FDA granted Orphan Drug Designation to NanoViricides’ broad-spectrum antiviral candidate NV-387 for the treatment of measles.
Stocktwits

Advertisement|Remove ads.